Dominic Magirr
Dominic Magirr
Verified email at novartis.com - Homepage
Title
Cited by
Cited by
Year
A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection
D Magirr, T Jaki, J Whitehead
Biometrika 99 (2), 494-501, 2012
1202012
Some recommendations for multi-arm multi-stage trials
J Wason, D Magirr, M Law, T Jaki
Statistical methods in medical research 25 (2), 716-727, 2016
722016
Sample size reassessment and hypothesis testing in adaptive survival trials
D Magirr, T Jaki, F Koenig, M Posch
PloS one 11 (2), e0146465, 2016
362016
Flexible sequential designs for multi‐arm clinical trials
D Magirr, N Stallard, T Jaki
Statistics in Medicine 33 (19), 3269-3279, 2014
292014
Considerations on covariates and endpoints in multi‐arm multi‐stage clinical trials selecting all promising treatments
T Jaki, D Magirr
Statistics in Medicine 32 (7), 1150-1163, 2013
232013
Simultaneous confidence intervals that are compatible with closed testing in adaptive designs
D Magirr, T Jaki, M Posch, F Klinglmueller
Biometrika 100 (4), 985-996, 2013
222013
Modestly weighted logrank tests
D Magirr, CF Burman
Statistics in medicine 38 (20), 3782-3790, 2019
162019
Influence of genetic background on bleeding phenotype in the tail-tip bleeding model and recommendations for standardization: communication from the SSC of the ISTH
A Schiviz, D Magirr, P Leidenmühler, M Schuster, EM Muchitsch, ...
Journal of thrombosis and haemostasis: JTH 12 (11), 1940-1942, 2014
102014
Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9‐mediated dose requirements of vitamin K antagonist therapy: a pilot study
S Brunner‐Ziegler, B Jilma, D Magirr, R Sunder‐Plassmann, GA Giurgea, ...
British journal of haematology 167 (4), 547-553, 2014
92014
The r package mams for designing multi-arm multi-stage clinical trials
T Jaki, P Pallmann, D Magirr
Journal of Statistical Software 88 (1), 1-25, 2019
82019
MAMS: Designing multi-arm multi-stage studies. R package, version 0.7
T Jaki, D Magirr, P Pallmann
82015
Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels
M Żebrowska, M Posch, D Magirr
Statistics in medicine 35 (12), 1972-1984, 2016
52016
Non‐proportional hazards in immuno‐oncology: Is an old perspective needed?
D Magirr
Pharmaceutical Statistics 20 (3), 512-527, 2021
42021
Phase I study of orally administered 14 Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and …
A MacDonald, G Scarfe, D Magirr, T Sarvotham, J Charlton, W Brugger, ...
Cancer chemotherapy and pharmacology 83 (4), 787-795, 2019
42019
Block response‐adaptive randomization in clinical trials with binary endpoints
D Magirr
Pharmaceutical statistics 10 (4), 341-346, 2011
42011
Optimized multiple testing procedures for nested sub-populations based on a continuous biomarker
AC Graf, D Magirr, A Dmitrienko, M Posch
Statistical methods in medical research 29 (10), 2945-2957, 2020
32020
Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups
A Allison, T Edwards, R Omollo, F Alves, D Magirr, NDE Alexander
Trials 16 (1), 1-11, 2015
22015
Package ‘MAMS’
T Jaki, D Magirr, MT Jaki
2021
The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross …
D Magirr, CF Burman
Statistics in Biopharmaceutical Research, 1-2, 2021
2021
Designing group sequential clinical trials when a delayed effect is anticipated: A practical guidance
D Magirr, JL Jiménez
arXiv preprint arXiv:2102.05535, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–20